Association of ST6GAL1 and CYP19A1 polymorphisms in the 3′-UTR with astrocytoma risk and prognosis in a Chinese Han population

Table 1 Relationship between clinicopathologic parameters and overall and progression-free survival of 365 astrocytoma patients

Variables		Frequency	Percent	Overall survival (OS)			Progression-free survival (PFS)
Variables		Frequency	Percent	χ²	Log-Rank p	1-year OS rate	χ²	Log-Rank p	1/2/3-year PFS rate
Sex	Male	205	56.2	1.720	0.190	33.70%	2.923	0.087	21.1%/12.6%/8.3%
Sex	Female	160	43.8			33.80%			11.3%/9.3%/7.6%
Age	< 40	155	42.5	3.279	0.070	33.90%	3.351	0.067	18.8%/16.1%/12.7%
Age	≥40	210	57.5			33.10%			15.4%/6.6%/4.7%
WHO grade	I	36	9.9	1.956	0.376	30.60%	2.267	0.322	22.2%/16.7%/−
	II	202	55.3			33.20%			17.3%/10.8%/9.8%
	III	127	34.8			29.10%			14.5%/8.9%/4.4%
Surgical method	GTR	248	68.0	39.958	< 0.001	36.30%	170.895	< 0.001	24.1%/15.0%/11.3%
	NTR	114	31.2			21.90%			1.8%/−/−
	STR	3	0.8			0.00%			0/−/−
Radiotherapy	No	40	11.0	1.213	0.545	45.00%	4.962	0.084	17.5%/−/−
	Gamma knife	222	60.8			33.80%			16.3%/7.1%/6.4%
	Conformal radiotherapy	103	28.2			21.40%			17.8%/16.7%/10.6%
Chemotherapy	No	219	60.0	25.403	< 0.001	26.90%	15.193	0.002	16.0%/6.8%/5.1%
	Platinum-based	75	20.5			26.70%			12.0%/−/4.0%
	ACNU	41	11.3			43.90%			10.0%/−/−
	TMZ	30	8.2			60.00%			45.6%/41.5%/−
Status	Survival	22	6.0
	Missing	15	4.1
	Death	328	89.9

Log-rank p values were calculated using the Chi-Square test
Bold values indicate a significant difference (p < 0.05)
GTR Gross total resection, NTR Near-total resection, STR Sub-total resection, ACNU Nimustine, TMZ Temozolomide

ISSN: 1471-2407